Head Office +91 8729085230
Guru Angad Nagar,
New Delhi 110092
09.00 to 18.00 Monday to Saturday
Get Free Consultation
Head Office +91 8729085230
Guru Angad Nagar,
New Delhi 110092
09.00 to 18.00 Monday to Saturday
The Global Liposome Drug Delivery market is expected to offer an $ opportunity of USD 5,469.60 million. Global market size was stood at USD 4,744.10 million in estimated year i.e. 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.87% from 2024 to 2035.
Global Market Size, Forecast, and Trend Analysis During Forecast Period 2022 - 2035:
| Base Year | 2022 |
| Forecast Year | 2024-2035 |
| CAGR | 9.87% |
| Base Year Market Size (2023) | USD 4,744.10 Million |
| Forecast Year Market Size (2035) | USD 10,213.70 Million |
The growing cases of chronic disease across the globe and surging demand for effective and efficient therapeutics considred to be the main market driver pushing market prospects. Effective drug delivery system is needed to provide appropriate therapeutics options. As a result, drugs are encapsulated into liposomes. In contrast to traditional drug delivery systems, liposomal based drug delivery system provides better protection of drugs from degradation and clearance, improved therapeutic effects, and most importantly lower toxic side effects.
Surging technological advances in liposomal drug delivery systems, rising investment, exploration of new indications, enhanced superiority are the main driving factors pertaining to liposomal drug delivery.
According to NCBI research, merely 12-14 types of liposomal products have been approved by regulators, this means, the benefit provided by the liposomal drug delivery system has not been exploited completely. Doxil(Doxorubicin HCl liposome injection) was the first approved product by USFDA in1995. Some of the leading available products in the market are Doxil Caelyx; DaunoXome; AmBisome; DepoCyt; DepoCyte; Myocet; Marqibo; Vyxeos; Shingrix; Onivyde among others.
Report has investigated the leading market products based on certain parameters such as,
There are four main products with micron diameters those are Mepact, DepoCyt (cytarabine liposome suspension), DepoDur (morphine sulfate extended-release liposome injection), and Exparel (bupivacaine liposome injectable suspension).
Liposomal has find its application in various areas such as drug delivery, cosmetics, adjuvants in vaccination, signal enhancers/carriers in medical diagnostics.
Growth Enablers
Challenges
Strategic Insights: Number of commercially available liposomal drugs are in use for various indications, such as fungal infections, cancer therapy, pain management, photo-dynamic therapy, pulmonary infections, vaccines, acute hepatitis B and nutritional products. Lots of opportunity lies in these segments.
Report has investigated the market segment attractiveness evaluation across indications.
The proliferation in the number of USFDA approval arouse the interest in liposomal drug delivery system from range of players. Liposome-based delivery technology, encompasses stealth liposomes, gas-filled liposomes, non-PEGylated liposomes, and DepoFoam™ technology, and newer liposomes for dedicated immunotherapy, are exploited.
Report Opportunity Analysis Outlook: Liposomal based drug delivery systems have potential to target delivery, avoid tissue toxicity, enhanced drug penetration, longer half-life and improved therapeutic effects. Report have investigated these data point in details.
Regulatory Landscape: Report has explored the EMA and FDA Regulations That Affect Complex Drug Product Development. Upheaval in regulatory policies have repercussion on current and future R&D investment. For instance, USFDA and Canadian regulatory guidelines support liposomal formulations for anti-fungal and anti-cancer treatments. Liposomes have been problematic within the regulatory framework on USFDA, that distinguish drugs, devices, biologics, or their combinations
Liposome Drug Delivery Regional Market Outlook:
North America: The liposome drug delivery market in North America is accounted for nearly 38.7% of the global market in terms of revenue. North America is seems lucrative due to future prospects. There are numerous factors driving the market such as favourable reimbursement policies to payors for these expensive therapeutics. Addressing market unmet need, create new markets that consistently the driving force for pharmaceutical innovations. Major driving force in the region is the prevalence of chronic diseases, as CDC data approximately 40% of US population suffer at least two chronic diseases. Region has well-established robust pipeline of liposomal drug, which is expected to witness in the near future.
Europe Market Forecast: Europe is considered as the second largest market.
Asia Pacific: The Asia Pacific region has considerable potential for liposomal drug development due to the increasing incidence of chronic disease. APAC region expected to provide huge opportunity in the future owing to growing disease prevalence across regions.
Our in-depth analysis of the Global Liposome Drug Delivery Market includes the following segments:
| Global Liposome Drug Delivery Market | |||
| Base Year: | 2022 | Forecast Period: | 2024-2035 |
| Historical Data: | 2022 | Market Size in 2023: | USD 4,744.10 Million |
| Forecast Period 2024-35 CAGR: | 9.87% | Market Size in 2035: | USD 10,213.70 Million |
| Segments Covered: | By Product |
| |
| By Technology |
| ||
| By Application |
| ||
| By Region |
| ||
| Key Market Drivers: |
| ||
| Key Market Restraints: |
| ||
| Key Trends: |
| ||
| Companies Covered in the Report: |
| ||